Celsion (NASDAQ:CLSN) plummets 65% premarket on robust volume in reaction to its announcement that the independent Data Monitoring Committee (DMC) has recommended the termination of the Phase 3 OPTIMA study evaluating ThermoDox, combined with radiofrequency ablation (RFA), in patients with hepatocellular carcinoma or primary liver cancer.
The DMC made its recommendation based on a pre-planned interim safety and efficacy analysis that showed the study was unlikely to achieve the primary endpoint after exceeding a futility threshold value.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.